전체 프로그램 | 바이오모아

ADCBiologicstaleChangchun GeneScience Pharmaceu…Phase 1

GenSci139 (GenSci139)

Advanced Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1

임상시험 1상태 RECRUITING

CGTBiologicstaleInstitut National de la Santé E…Phase 1

Gene Therapy product CYL-02 = plasmid DNA pre-complexed to linear polyethylenimine encoding sst2 + dck::umk genes (Gene Therapy product CYL-02 = plasmid DNA pre-complexed to linear polyethylenimine encoding sst2 + dck::umk genes)

Pancreatic Adenocarcinoma · Pancreatic Adenocarcinoma

#PancreaticAdenocarcinoma#CGT#Phase1#세포유전치료#CAR-T+2

임상시험 1상태 ACTIVE

CGTBiologicstaleNanoscope Therapeutics Inc.Phase 2

Gene Therapy-vMCO-010 (Gene Therapy-vMCO-010)

Stargardt Disease · Stargardt Disease

#StargardtDisease#CGT#Phase2#세포유전치료#CAR-T+2

임상시험 1상태 ACTIVE

CGTAAVBiologicstaleTippi MackenziePhase 1

Gene Transfer with an AAV9 Vector Expressing Human ß-galactosidase (Gene Transfer with an AAV9 Vector Expressing Human ß-galactosidase)

GM1 Gangliosidoses; GM1 Gangliosidosis, Type I · GM1 Gangliosidoses

#GM1Gangliosidoses#CGT#Phase1#세포유전치료#CAR-T+4

임상시험 1상태 RECRUITING

AntibodyBiologicstaleHenan Provincial People's Hospi…Preclinical

Gene evolution and molecular response under Bevacizumab treatment (Gene evolution and molecular response under Bevacizumab treatment)

Genetic Change · Genetic Change

#GeneticChange#Antibody#Preclinical#항체#면역항체+2

임상시험 1상태 RECRUITING

CGTBiologicstaleShanghai Zhongshan HospitalPhase 1

First dose group (Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :1.0×10^8, Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :1.0×10^8(First dose group))

HCC · HCC

#HCC#CGT#Phase1#세포유전치료#CAR-T+2

임상시험 1상태 RECRUITING

CGTBiologicstaleGuangzhou JOYO Pharma Co., LtdPhase 1

Second dose group (Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :2.5×10^8, Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :2.5×10^8(Second dose group))

HCC · HCC

#HCC#CGT#Phase1#세포유전치료#CAR-T+2

효능 ORR 38%임상시험 1상태 RECRUITING

CGTBiologicstaleShanghai Zhongshan HospitalPhase 1

Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :5.0×10^8（Third dose group） (Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :5.0×10^8（Third dose group）)

HCC · HCC

#HCC#CGT#Phase1#세포유전치료#CAR-T+2

임상시험 1상태 RECRUITING

CGTBiologicstaleGenSight BiologicsPhase 2

Gene therapy: GS030-DP AND Medical device: GS030-MD (Gene therapy: GS030-DP AND Medical device: GS030-MD)

Non-syndromic Retinitis Pigmentosa · Non-syndromic Retinitis Pigmentosa

#Non-syndromicRetinitisPigmentosa#CGT#Phase2#세포유전치료#CAR-T+2

임상시험 1상태 RECRUITING

CGTBiologicstaleChildren's Hospital Medical Cen…Phase 2

Gene-Corrected Macrophages administered by bronchoscopic instillation (Gene-Corrected Macrophages administered by bronchoscopic instillation)

Hereditary Pulmonary Alveolar Proteinosis · Hereditary Pulmonary Alveolar Proteinosi

#HereditaryPulmonaryAlveolarProte#CGT#Phase2#세포유전치료#CAR-T+2

임상시험 1상태 RECRUITING

CGTBiologicstaleWugen, Inc.Preclinical

Genetic: WU-CART-007 (Genetic: WU-CART-007)

T-cell Acute Lymphoblastic Leukemia; T-cell Lymphoblastic Lymphoma · T-cell Acute Lymphoblastic Leukemia

#T-cellAcuteLymphoblasticLeukemia#CGT#Preclinical#세포유전치료#CAR-T+3

임상시험 1상태 ACTIVE

CGTBiologicstaleMuscular Dystrophy AssociationPhase 1

Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort (Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort)

Muscular Dystrophies · Muscular Dystrophies

#MuscularDystrophies#CGT#Phase1#세포유전치료#CAR-T+2

임상시험 1상태 ACTIVE

CGTBiologicstaleFate TherapeuticsPreclinical

Genetically engineered NK cells (Genetically engineered NK cells)

Hematological Malignancy · Hematological Malignancy

#HematologicalMalignancy#CGT#Preclinical#세포유전치료#CAR-T+2

효능 ORR 0%임상시험 1상태 DISCONTINUED

CGTBiologicstaleAdaptimmunePreclinical

Genetically engineered T Cell Receptors (Genetically engineered T Cell Receptors)

Solid and Hematological Malignancies · Solid and Hematological Malignancies

#SolidandHematologicalMalignancie#CGT#Preclinical#세포유전치료#CAR-T+2

효능 ORR 0%임상시험 1상태 DISCONTINUED

AntibodystaleChangchun GeneScience Pharmaceu…Phase 1

Gentulizumab (Gentulizumab)

Solid Tumor; Non-Hodgkin Lymphoma · Solid Tumor

#SolidTumor#Antibody#Phase1#항체#면역항체+3

임상시험 1상태 DISCONTINUED

AntibodystaleInstitut für Klinische Krebsfor…Phase 2

Glofitamab as Consolidation therapy (Glofitamab as Consolidation therapy)

Relapsed /Refractory DLBCL · FRα

#FR#Antibody#Phase2#항체#면역항체+4

임상시험 1상태 RECRUITING

AntibodystaleInstitut für Klinische Krebsfor…Phase 2

Glofitamab, Gemcitabine, and Oxaliplatin as Induction Therapy (Glofitamab, Gemcitabine, and Oxaliplatin as Induction Therapy)

Relapsed /Refractory DLBCL · FRα

#FR#Antibody#Phase2#항체#면역항체+4

임상시험 1상태 RECRUITING

ADCBiologicstaleRochePhase 2

Glofitamab, Polatuzumab Vedotin, Gemcitabine, and Oxaliplatin as Induction Therapy (Glofitamab, Polatuzumab Vedotin, Gemcitabine, and Oxaliplatin as Induction Therapy)

Aggressive B-Cell Lymphoma · Aggressive B-Cell Lymphoma

#AggressiveB-CellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

임상시험 1상태 RECRUITING

ADCBiologicstaleRochePhase 2

Glofitamab, Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Prednisone as Induction Therapy (Glofitamab, Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Prednisone as Induction Therapy)

Diffuse Large B-Cell Lymphoma · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

임상시험 1상태 RECRUITING

ADCBiologicstaleRochePhase 2

Glofitamab; Polatuzumab vedotin; Zuberitamab; Cyclophosphamide; Doxorubicin; Prednisone (Glofitamab; Polatuzumab vedotin; Zuberitamab; Cyclophosphamide; Doxorubicin; Prednisone)

DLBCL - Diffuse Large B Cell Lymphoma; Chemo-free Therapy · DLBCL - Diffuse Large B Cell Lymphoma

#DLBCL-DiffuseLargeBCellLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2

임상시험 1상태 RECRUITING

118 / 177 페이지

← 이전 다음 →

갱신 기록 없음 · 14일 주기 · 방문 0 / 1,453